Asia-Pacific markets rise as investors assess renewed Middle East hostilities

Novartis shares fell as much as 3.6% in early Monday trading after the pharmaceutical company announced an experimental drug failed to reduce the risk of cardiovascular events compared to placebo in a late-stage trial. The disappointing results mark a setback for the Swiss drugmaker's pipeline development.

The decline in Novartis came as broader Asia-Pacific markets opened higher Monday, building on gains from Friday's session. However, the Novartis trial failure demonstrates how individual stock catalysts can override regional momentum.

The late-stage trial failure represents a significant clinical disappointment, as cardiovascular drugs targeting event reduction typically command premium valuations when successful. The 3.6% early drop suggests investors are repricing the company's pipeline value following the negative data.